Join us at ESMO 2024 for updates from our parallel lead programs for ALK+ and ROS1+ NSCLC.
NVL-655 and zidesamtinib are investigational drugs and have not received marketing approval by any regulatory authorities.
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Presentation Number: 1253O
Presenting Author: Alexander E. Drilon, M.D.
Date: Saturday, 14 September 2024
Lecture Time: 09:30 – 09:40 CEST
Location: Barcelona Auditorium, Hall 2, Fira Barcelona Gran Via, Barcelona, Spain
Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors
Presentation Number: 1256MO
Presenting Author: Benjamin Besse, M.D., Ph.D.
Date: Saturday, 14 September 2024
Lecture Time: 10:25 – 10:30 CEST
Location: Santander Auditorium, Hall 5, Fira Barcelona Gran Via, Barcelona, Spain
Profiling of Zidesamtinib and Other ROS1 Inhibitors in an Intracranial CD74-ROS1 G2032R Preclinical Model
Presentation Number: 8P
Presenting Author: Anupong Tangpeerachaikul, Ph.D.
Date: Sunday, 15 September 2024
